Adicet Bio
ACET
76 hedge funds and large institutions have $63M invested in Adicet Bio in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 26 reducing their positions, and 14 closing their positions.
29% more capital invested
Capital invested by funds: $48.9M → $63M (+$14.2M)
8% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 26
0.35% less ownership
Funds ownership: 5.18% → 4.83% (-0.35%)
8% less funds holding
Funds holding: 83 → 76 (-7)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
96% less call options, than puts
Call options by funds: $4K | Put options by funds: $90K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$583K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$273K |
| 3 |
Two Sigma Investments
New York
|
+$185K |
| 4 |
Two Sigma Advisers
New York
|
+$182K |
| 5 |
D.E. Shaw & Co
New York
|
+$139K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.41M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.09M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$477K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$457K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$265K |
ACET Hedge Fund Activity: Q4 2023 in Review
76 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Adicet Bio (ACET) for Q4 2023, worth a combined $63M — up 29% from $48.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ACET and 8 opened new positions — a net loss of 6 holders — while 26 trimmed existing stakes and 28 added.
The largest buyer was Millennium Management, adding an estimated $583K. The largest seller was Morgan Stanley, cutting an estimated $1.41M.
- 76 institutional investors held Adicet Bio (ACET) as of Q4 2023, down from 83 in Q3 2023.
- Funds reported $63M of Adicet Bio stock for Q4 2023, up 29% quarter-over-quarter.
- 8 funds opened new Adicet Bio positions in Q4 2023 and 14 closed out, a net change of -6 holders.
- The largest Adicet Bio buyer in Q4 2023 was Millennium Management, an estimated $583K added.
- The largest Adicet Bio seller in Q4 2023 was Morgan Stanley, an estimated $1.41M sold.
Based on aggregated 13F filings for Q4 2023.